|
|
 |
|
Viewing report
|
|
|
|
Polycystic Ovarian Syndrome - Drug Pipeline Analysis and Market Forecasts to 2016
GlobalData, April 2010, Pages: 41
Polycystic Ovarian Syndrome - Drug Pipeline Analysis and Market Forecasts to 2016
Summary
“Polycystic Ovarian Syndrome- Drug Pipeline Analysis and Market Forecasts to 2016” is an essential source of information and analysis on the global polycystic ovarian syndrome market. The report identifies the key trends shaping and driving the global polycystic ovarian syndrome market. The report also provides insight on the prevalent competitive landscape and the emerging players expected to bring significant shift in the market positioning of the existing market leaders. Most importantly, the report provides valuable insight on the pipeline products within the global polycystic ovarian syndrome sector.
This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by Our team of industry experts.
Scope
The report provides information on the key drivers and challenges of the global polycystic ovarian syndrome market. Its scope includes:
- Annualized global polycystic ovarian syndrome market revenues data from 2001 to 2009, forecast for seven years to 2016.
- Key geographies covered in this report are the US, the UK, Italy, Spain, Germany, France and Japan.
- Pipeline analysis data providing a split across different phases, mechanism of action being developed and emerging trends. The key classes of mechanism of action include fat breakdown inhibitors, estrogen antagonists, female gamete enhancers, insulin secretion stimulators, gastric lipase inhibitor HMG CoA inhibitors.
- Analysis of the current and future market competition in the global polycystic ovarian syndrome market. Key market players covered include Sanofi Aventis, Bristol Myers Squibb, Novartis Pharmaceuticals, Sandoz Inc, Genpharm Inc, Ivax Pharmaceuticals Inc, Barr Laboratories Inc, Par Pharmaceuticals Inc. Genpharm Inc, Merck CoA and Catalysis SL.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs and implications for the future polycystic ovarian syndrome market.
Reasons to buy
The report will enhance your decision making capability in a more rapid and time sensitive manner. It will allow you to:
- Develop and design your in-licensing and out-licensing strategies through review of pipeline products and technologies and by identifying companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global polycystic ovarian syndrome market.
- Drive revenues by understanding key trends, innovative products and technologies, market segments and companies likely to impact the global polycystic ovarian syndrome market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- What’s the next big thing in the global polycystic ovarian syndrome market landscape? - Identify, understand and capitalize.
Customers who bought this item also bought
Polycystic Ovarian Syndrome (PCOS) Therapeutics - Pipeline Assessment and Market Forecasts to 2018
Polycystic Ovarian Syndrome Global Clinical Trials Review, H2 2011
The World Market for Gynaecology, 2007-2017
Polycystic Ovarian Syndrome Global Clinical Trials Review, Q2, 2011
Polycystic Kidney Disease (PKD) Therapeutics - Pipeline Assessment and Market Forecasts to 2019
Global Ovarian Cancer Drug Pipeline Capsule - 2012
Polycystic Ovarian Syndrome - Pipeline Review, H1 2012
Clinical Trial Endpoints in Oncology - Inclusion of Surrogate Endpoints and Shorter Endpoints Will Ensure Faster Clinical Trials in Oncology
Cushing's Syndrome Therapeutics - Pipeline Assessment and Market Forecasts to 2019
Sjögren's Syndrome Therapeutics - Pipeline Assessment and Market Forecasts to 2019
|
|
|
|
